Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1979 1
1982 2
1983 1
1986 2
1988 1
1989 2
1990 5
1991 1
1992 4
1993 8
1994 7
1995 7
1996 7
1997 14
1998 8
1999 12
2000 14
2001 11
2002 14
2003 16
2004 18
2005 17
2006 19
2007 10
2008 14
2009 18
2010 18
2011 26
2012 23
2013 37
2014 26
2015 31
2016 23
2017 25
2018 25
2019 25
2020 20
2021 13
2022 16
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

496 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Male Breast Carcinoma In Situ"
Page 1
Male breast cancer: an update.
Fox S, Speirs V, Shaaban AM. Fox S, et al. Virchows Arch. 2022 Jan;480(1):85-93. doi: 10.1007/s00428-021-03190-7. Epub 2021 Aug 30. Virchows Arch. 2022. PMID: 34458944 Review.
Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the incidence has increased worldwide. ...Reporting and staging are similar to female breast cancer. Metastatic lesions to the male breast do occur and …
Male breast cancer (MBC) is rare, accounting for less than 1% of all breast cancer but the incidence has increased worl …
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. Tarantino P, et al. JAMA Oncol. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286. JAMA Oncol. 2022. PMID: 35737367 Free PMC article.
IMPORTANCE: It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 breast cancer. OBJECTIVE: To investigate whether low ERBB2 expression is associated with distinct clinicopathologic characteristics an …
IMPORTANCE: It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 …
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D, Howard FM. Peiffer DS, et al. JAMA Oncol. 2023 Apr 1;9(4):500-510. doi: 10.1001/jamaoncol.2022.7476. JAMA Oncol. 2023. PMID: 36821125 Free PMC article.
IMPORTANCE: Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu)-low breast cancer, a large-scale, nationally applicable comparison of ERBB2-low vs ERBB2-negative breast cancer is needed. .. …
IMPORTANCE: Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu) …
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Valtorta E, et al. Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. Mod Pathol. 2015. PMID: 26449765 Free article. Clinical Trial.
Collegial revision of an archival test cohort of colorectal cancer samples led to specific recommendations for adapting current breast and gastric cancer criteria for scoring ERBB2 in colorectal cancer. ...In a phase II trial of trastuzumab and lapatinib in a cetuximab-res …
Collegial revision of an archival test cohort of colorectal cancer samples led to specific recommendations for adapting current breast …
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM. Ross JS, et al. Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16. Cancer. 2018. PMID: 29338072 Free PMC article.
Other significant differences in mutation frequency were observed for genes in the PI3K/MTOR and mismatch repair pathways. CONCLUSIONS: Although observed less often than in breast or upper gastrointestinal carcinomas, indications for which anti-HER2 therapies are approved, …
Other significant differences in mutation frequency were observed for genes in the PI3K/MTOR and mismatch repair pathways. CONCLUSIONS: Alth …
Breast cancer.
Berg JW, Hutter RV. Berg JW, et al. Cancer. 1995 Jan 1;75(1 Suppl):257-69. doi: 10.1002/1097-0142(19950101)75:1+<257::aid-cncr2820751311>3.0.co;2-y. Cancer. 1995. PMID: 8001000
Relative frequencies, incidence rates, and 5-year relative survival rates were examined by selected variables of interest. Invasive and in situ breast carcinomas and sarcomas were analyzed separately. RESULTS: Infiltrating duct carcinoma was the largest group of fem …
Relative frequencies, incidence rates, and 5-year relative survival rates were examined by selected variables of interest. Invasive and in s …
DCIS in Male and Aged Women with Comorbidities.
Krawczyk N, Fehm T, Banys-Paluchowski M. Krawczyk N, et al. Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S120-S127. doi: 10.21614/chirurgia.116.5.suppl.S120. Chirurgia (Bucur). 2021. PMID: 34967320 Free article.
DCIS in aged women has an excellent prognosis and the risk of local recurrence is lower compared to younger patients. ...Pure DCIS in men is a very rare disease representing approximately 5% of all male breast cancers. The most common type of DCIS in men is a …
DCIS in aged women has an excellent prognosis and the risk of local recurrence is lower compared to younger patients. ...Pure DCIS in …
Progression from ductal carcinoma in situ to invasive breast cancer: revisited.
Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, Reis-Filho JS. Cowell CF, et al. Mol Oncol. 2013 Oct;7(5):859-69. doi: 10.1016/j.molonc.2013.07.005. Epub 2013 Jul 12. Mol Oncol. 2013. PMID: 23890733 Free PMC article. Review.
Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells that is separated from the breast stroma by an intact layer of basement membrane and myoepithelial cells. ...Currently, it is not possible to predict accurately whi …
Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells that is separated from the breast …
Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features.
Hou R, Grimm LJ, Mazurowski MA, Marks JR, King LM, Maley CC, Lynch T, van Oirsouw M, Rogers K, Stone N, Wallis M, Teuwen J, Wesseling J, Hwang ES, Lo JY. Hou R, et al. Radiology. 2022 Apr;303(1):54-62. doi: 10.1148/radiol.210407. Epub 2022 Jan 4. Radiology. 2022. PMID: 34981975 Free PMC article.
Background Improving diagnosis of ductal carcinoma in situ (DCIS) before surgery is important in choosing optimal patient management strategies. ...High specificity (90%) corresponded to a sensitivity of 37%, positive predictive value of 41%, and odds ratio of 5.0 ( …
Background Improving diagnosis of ductal carcinoma in situ (DCIS) before surgery is important in choosing optimal patient management …
Breast Cancer in Male Adolescents and Young Adults.
Flaherty DC, Bawa R, Burton C, Goldfarb M. Flaherty DC, et al. Ann Surg Oncol. 2017 Jan;24(1):84-90. doi: 10.1245/s10434-016-5586-4. Epub 2016 Sep 20. Ann Surg Oncol. 2017. PMID: 27650826
However, few data exist detailing either in situ or invasive breast cancer in male AYAs. METHODS: All male AYA breast cancer cases were identified in the National Cancer Data Base (1998-2010). ...RESULTS: Of 677 male AYAs, 122 patients (18 %) ha …
However, few data exist detailing either in situ or invasive breast cancer in male AYAs. METHODS: All male AYA breas …
496 results